- Supply agreements underway with a major Japanese pharma firm and a U.S. partner Initial shipment expected as early as August - Expanding business beyond pharmaceuticals into specialized medical devices Further expansion possible into Canada, India, and other markets - Operating profit margin exceeds 40% Thrombin sales projected to surpass 10 billion KRW by 2027 Reyon Pharmaceutical, the sole manufacturer of finished thrombin pharmaceuticals in South Korea, is embarking on a global market push...

- Partner Elisigen unveils the 44-week clinical results of the mid-dose cohort for NG101 for the first time at ASRS. - Proven to reduce wet macular degeneration injection frequency by 90% even at an ultra-low doseless than 10% of competitors doses. - Reyon Pharmaceutical secures exclusive manufacturing rights, greenlighting advanced GMP commercial production at its new Chungju plant. NG101, a next-generation pipeline co-developed by Reyon Pharmaceutical and its partner Elisigen, has unveiled ov...

- Clinical trials for NG101 show smooth progress from low-dose to medium-dose (Cohort 2) 44-week results to be unveiled - Selected to present in the gene therapy session alongside Eli Lilly, validating technological excellence - Reyon Pharmaceutical to exclusively handle global production and supply of NG101 via its Chungju GMP facility Elisigen, a gene therapy research and development company and a partner of REYON PHARM, announced that it will present the 44-week interim results of its Phase ...

- Leading Japanese gene therapy companies are scheduled to visit the Chungju Smart Plant. - Possibility of collaboration on AAV and pDNA manufacturing ahead of global clinical trials and commercialization. - Visits from European multinationals and large domestic pharmaceutical companies continue, drawing increased industry attention. Major gene therapy development companies from Japan are reported to make a series of visits to Reyon Pharmaceuticals Chungju Smart Plant this coming July. The indu...